Early-stage cancer immunotherapy represents a promising yet underexplored frontier in cancer research. While immunotherapeutic strategies have achieved ...

Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...

Pheast Therapeutics, a clinical-stage biotechnology company advancing macrophage-directed immunotherapies for cancer, today announced that it will present three abstracts at the American Association ...

Advances in tissue-based technology in the past few years have created unprecedented opportunities to identify biomarkers of disease processes, especially within oncology by using multi-omics ...

Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, it is worth highlighting ...

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and ...

Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue. A new “Tumor Activated Therapy™” in development at the small ...

The inflammatory tumor microenvironment (TME) is a complex network of cancer, immune, and stromal cells interacting through cytokines and growth factors to drive tumor growth, angiogenesis, and immune ...

The tumor microenvironment (TME) consists of mediators surrounding a tumor, including diverse cell types, blood vessels, and other cellular components. Certain elements of the TME can benefit patients ...

Northwestern Medicine scientists have discovered that specialized immune cells within the glioblastoma tumor metabolize ...